← back to search

Bishoy M. Faltas

Cornell University · US
Area of research
Surgery · Cancer Research
Research interest
Research interests include Bladder and Urothelial Cancer Treatments, Cancer Genomics and Diagnostics, Epigenetics and DNA Methylation, and Urinary and Genital Oncology Studies.
h-index
40
citations
16,218
works
265
NIH funding
primary concept
email

Recent publications

Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group
European Urology 2025cited by 28position: middledoi
Predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer via interpretable multimodal deep learning
npj Digital Medicine 2025cited by 25position: middledoi
Spatial–Temporal Diversity of Extrachromosomal DNA Shapes Urothelial Carcinoma Evolution and the Tumor Immune Microenvironment
Cancer Discovery 2025cited by 20position: middledoi
HER2 and urothelial carcinoma: current understanding and future directions
Nature Reviews Urology 2025cited by 15position: middledoi
Error-corrected flow-based sequencing at whole-genome scale and its application to circulating cell-free DNA profiling
Nature Methods 2025cited by 14position: middledoi
The interplay of mutagenesis and ecDNA shapes urothelial cancer evolution
Nature 2024cited by 50position: lastdoi
FGFR Inhibition in Urothelial Carcinoma
European Urology 2024cited by 29position: middledoi
Circulating and urinary tumour DNA in urothelial carcinoma — upper tract, lower tract and metastatic disease
Nature Reviews Urology 2023cited by 53position: middledoi
Novel Use of Circulating Tumor DNA to Identify Muscle-invasive and Non–organ-confined Upper Tract Urothelial Carcinoma
European Urology 2023cited by 37position: middledoi
Immunotherapy in the Treatment of Localized Genitourinary Cancers
JAMA Oncology 2023cited by 13position: middledoi
Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma
British Journal of Cancer 2022cited by 42position: lastdoi
The Cytidine Deaminase APOBEC3G Contributes to Cancer Mutagenesis and Clonal Evolution in Bladder Cancer
Cancer Research 2022cited by 35position: lastdoi
Tumor-Infiltrating Myeloid Cells Confer <i>De Novo</i> Resistance to PD-L1 Blockade through EMT–Stromal and Tgfβ-Dependent Mechanisms
Molecular Cancer Therapeutics 2022cited by 8position: middledoi
Author Correction: A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns
Nature Communications 2022cited by 2position: middledoi
A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns
Nature Communications 2020cited by 235position: middledoi
Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes
Nature Reviews Urology 2020cited by 195position: middledoi
Sex differences in oncogenic mutational processes
Nature Communications 2020cited by 125position: middledoi
Molecular Characterization of Upper Tract Urothelial Carcinoma in the Era of Next-generation Sequencing: A Systematic Review of the Current Literature
European Urology 2020cited by 99position: lastdoi
Epithelial plasticity can generate multi-lineage phenotypes in human and murine bladder cancers
Nature Communications 2020cited by 68position: middledoi
Clinical features of neuroendocrine prostate cancer
European Journal of Cancer 2019cited by 358position: middledoi
Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling
Nature Communications 2019cited by 209position: lastdoi
Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancer (mUC): Results from a phase I/II study.
Journal of Clinical Oncology 2019cited by 84position: middledoi
Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study
European Urology Oncology 2019cited by 48position: middledoi
Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer
JCO Precision Oncology 2019cited by 45position: middledoi
Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA
Cancer 2018cited by 100position: middledoi
Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine
Cancer Discovery 2017cited by 944position: middledoi
Clonal evolution of chemotherapy-resistant urothelial carcinoma
Nature Genetics 2016cited by 299position: firstdoi
Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response
JAMA Oncology 2015cited by 299position: middledoi
Recurrence Patterns After Open and Robot-assisted Radical Cystectomy for Bladder Cancer
European Urology 2015cited by 167position: middledoi
Sacituzumab Govitecan, a Novel Antibody–Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma
Clinical Genitourinary Cancer 2015cited by 105position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Olivier Elemento · Cornell University8 papers (2016–2025)Scott T. Tagawa · Cornell University6 papers (2015–2022)Joshua J. Meeks · University of Illinois Chicago6 papers (2020–2025)David M. Nanus · Cornell University5 papers (2015–2022)Juan Miguel Mosquera · Cornell University4 papers (2016–2022)Guru Sonpavde · AdventHealth Orlando4 papers (2018–2023)Roger Li · Southwestern Medical Center4 papers (2023–2024)Andrea Necchi · Second Foundation (United States)4 papers (2023–2025)Jeffrey S. Ross · SUNY Upstate Medical University4 papers (2023–2025)Ana M. Molina · Cornell University4 papers (2016–2022)Petros Grivas · Second Foundation (United States)4 papers (2018–2025)Philippe E. Spiess · The University of Texas Southwestern Medical Center4 papers (2023–2025)Andrea Sboner · Cornell University3 papers (2016–2022)Himisha Beltran · Harvard University3 papers (2016–2019)Seth P. Lerner · Elfi-Tech (Israel)3 papers (2019–2025)Rebecca J. Nagy · Guardant (United States)3 papers (2018–2022)John P. Sfakianos · Mount Sinai Medical Center3 papers (2020–2022)Matthew D. Galsky · Rutgers New Jersey Medical School3 papers (2020–2025)Rohan Bareja · NewYork–Presbyterian Hospital3 papers (2019–2020)Ashish M. Kamat · The University of Texas MD Anderson Cancer Center3 papers (2023–2025)